XENE: Azetukalner advances toward U.S. approval with robust data, premium pricing, and broad launch plans
Azetukalner is nearing NDA filing for focal onset seizures, with strong efficacy across four doses and plans for premium pricing. Launch will focus on epileptologists, expanding to general neurologists, and leverage a specialty distribution model. Pipeline includes neuropsychiatry and pain assets…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.